Molecular status of pituitary carcinoma and atypical adenoma that contributes the effectiveness of temozolomide

Abstract

There have been several reports of temozolomide (TMZ) treatment of pituitary carcinomas and atypical adenomas. O6-methyl-guanine-DNA methyltransferase is not the sole molecule determining the sensitivity to TMZ in pituitary carcinomas and atypical adenomas. The Japan Society of Hypothalamic and Pituitary Tumors study suggests that MSH6, one of mismatch repair pathway enzyme, fulfills a contributory role to the efficacy of TMZ treatment for pituitary carcinomas and atypical adenomas. The preserved MSH6 function might be essential for the responsiveness to TMZ treatment in pituitary carcinomas and atypical adenomas.

DOI: 10.1007/s00795-013-0050-z

2 Figures and Tables

050100201520162017
Citations per Year

Citation Velocity: 12

Averaging 12 citations per year over the last 3 years.

Learn more about how we calculate this metric in our FAQ.

Cite this paper

@article{Matsuno2013MolecularSO, title={Molecular status of pituitary carcinoma and atypical adenoma that contributes the effectiveness of temozolomide}, author={Akira Matsuno and Mineko Murakami and Katsumi Hoya and Shoko Merrit Yamada and Shinya Miyamoto and So Yamada and Jae-Hyun Son and Hajime Nishido and Fuyuaki Ide and Hiroshi Nagashima and Mutsumi Sugaya and Toshio Hirohata and Akiko Mizutani and Hiroko Okinaga and Yudo Ishii and Shigeyuki Tahara and Akira Teramoto and Robert Yoshiyuki Osamura}, journal={Medical Molecular Morphology}, year={2013}, volume={47}, pages={1-7} }